In our studies, we provide lipidomic analysis showing that sphingomyelin (SM), particularly palmitoyl-sphingomyelin (pSM), prominently accumulates in tau-brain extract (TBE)-treated microglia and suggest it as a possible therapeutic target for AD according to its abundance after tau treatment. Here, MAPT is linked to Alzheimer disease.